Deal Library / Pharma BD Deal Intelligence

Neurology Deals

The Pharma Closeout tracks 107 deals, $490.2B in disclosed deal value, 64 with a post-close Outcome Score for Neurology.

Median Critic Score: 75  ·  Median Outcome Score: 54

Best outcome: Novartis AG / Advanced Accelerator Applications S.A. (98)  ·  Weakest outcome: Allergan plc / Heptares Therapeutics Ltd. (12)

All 107 deals

• Novartis AG / Advanced Accelerator Applications S.A. — 2017 · $3.9B · Worked — the deal delivered on its rationale.
• Allergan plc / Merck & Co., Inc. (CGRP receptor antagonist program) — 2015 · $250M · Worked — the deal delivered on its rationale.
• Cephalon Inc. / Laboratoire L. Lafon S.A. (Group Lafon) — 2000 · $450M · Worked — the deal delivered on its rationale.
• Teva Pharmaceutical Industries Ltd. / Auspex Pharmaceuticals — 2015 · $3.5B · Worked — the deal delivered on its rationale.
• Teva Pharmaceutical Industries Ltd. / Biogal Pharmaceutical — 1995 · Worked — the deal delivered on its rationale.
• Novartis AG / PTC Therapeutics Inc. — 2024 · $2.9B · Worked — the deal delivered on its rationale.
• Jazz Pharmaceuticals PLC / GW Pharmaceuticals — 2021 · $7.2B · Worked — the deal delivered on its rationale.
• Regeneron Pharmaceuticals, Inc. / Alnylam Pharmaceuticals Inc. — 2019 · $1.0B · Worked — the deal delivered on its rationale.
• Johnson & Johnson / Intra-Cellular Therapies — 2025 · $14.6B · Worked — the deal delivered on its rationale.
• Bristol-Myers Squibb Company / Karuna Therapeutics — 2023 · $14.0B · Worked — the deal delivered on its rationale.
• Servier / Edgewise Therapeutics, Inc. — 2026 · $2.6B · Worked — the deal delivered on its rationale.
• Actavis plc / Forest Laboratories — 2014 · $25.0B · Worked — the deal delivered on its rationale.
• Sanofi SA / Genzyme Corporation — 2010 · $18.5B · Worked — the deal delivered on its rationale.
• Novartis AG / Hexal AG — 2002 · $8.3B · Worked — the deal delivered on its rationale.
• Merck KGaA / Serono SA — 2006 · $13.2B · Largely worked — most objectives met.
• Biogen Inc. / Reata Pharmaceuticals — 2023 · $7.3B · Largely worked — most objectives met.
• Jazz Pharmaceuticals PLC / Celator Pharmaceuticals — 2016 · $1.5B · Largely worked — most objectives met.
• Sarepta Therapeutics Inc. / Arrowhead Pharmaceuticals Inc. — 2024 · $1.1B · Largely worked — most objectives met.
• Pfizer Inc. / Biohaven Pharmaceutical Holding Company Ltd. — 2022 · $11.6B · Largely worked — most objectives met.
• Roche Holding AG / Repare Therapeutics Inc. — 2022 · $1.3B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / Evotec SE — 2023 · $4.0B · Largely worked — most objectives met.
• Bristol-Myers Squibb Company / BioArctic AB — 2024 · $1.4B · Largely worked — most objectives met.
• AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. — 2024 · $2.0B · Largely worked — most objectives met.
• Takeda Pharmaceutical Company Ltd. / Denali Therapeutics Inc. — 2018 · $1.2B · Largely worked — most objectives met.
• Eli Lilly and Company / Point Biopharma — 2023 · $1.4B · Largely worked — most objectives met.
• Teva Pharmaceutical Industries Ltd. / Ivax Corporation — 2005 · $7.4B · Largely worked — most objectives met.
• Eli Lilly and Company / AC Immune SA — 2017 · $2.0B · Mixed — partial payoff, real shortfalls.
• Teva Pharmaceutical Industries Ltd. / Barr Pharmaceuticals — 2008 · $7.5B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / CoLucid Pharmaceuticals — 2017 · $960M · Mixed — partial payoff, real shortfalls.
• QuantumCell ApS / AlzeCure Pharma AB — 2026 · $2.2B · Mixed — partial payoff, real shortfalls.
• Schering-Plough Corp. / Organon International — 2007 · $14.4B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / AlzeCure Pharma AB — 2026 · $1.0B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / Avid Radiopharmaceuticals, Inc. — 2010 · $800M · Mixed — partial payoff, real shortfalls.
• AbbVie Inc. / Aliada Therapeutics — 2024 · $1.4B · Mixed — partial payoff, real shortfalls.
• Eli Lilly and Company / 4E Therapeutics, Inc. — 2026 · Mixed — partial payoff, real shortfalls.
• Al Sirona (Luxembourg) Acquisition / Zentiva Group — 2018 · $2.4B · Mixed — partial payoff, real shortfalls.
• Schering-Plough Corp. / Organon & Co. — 2007 · $14.4B · Mixed — partial payoff, real shortfalls.
• Dr. Reddy's Laboratories / Betapharm — 2006 · $572M · Mixed — partial payoff, real shortfalls.
• STADA Arzneimittel / Eurogenerics — 1991 · $55M · Mixed — partial payoff, real shortfalls.
• Sanofi SA / Rhône-Poulenc — 1895 · Mixed — partial payoff, real shortfalls.
• Teva Pharmaceutical Industries Ltd. / Cephalon Inc. — 2011 · $6.8B · Mixed — partial payoff, real shortfalls.
• Valeant Pharmaceuticals International / Xcel Pharmaceuticals, Inc. — 2005 · $280M · Underwhelmed — fell short of the thesis.
• Otsuka Pharmaceutical Co., Ltd. / Avanir Pharmaceuticals, Inc. — 2014 · $3.5B · Underwhelmed — fell short of the thesis.
• Roche Holding AG / AC Immune SA — 2012 · $718M · Underwhelmed — fell short of the thesis.
• Roche Holding AG / AC Immune SA — 2012 · $570M · Underwhelmed — fell short of the thesis.
• Forest Laboratories, Inc. / Clinical Data, Inc. — 2011 · $1.2B · Underwhelmed — fell short of the thesis.
• Mitsubishi Tanabe Pharma Corporation / NeuroDerm Ltd. — 2017 · $1.1B · Underwhelmed — fell short of the thesis.
• Pfizer Inc. / InnoPharma, Inc. — 2014 · $360M · Underwhelmed — fell short of the thesis.
• Novartis AG / Takeda Pharmaceutical Company Ltd. — 2019 · $5.3B · Underwhelmed — fell short of the thesis.
• Abbott Laboratories / Facet Biotech Corporation — 2010 · $722M · Underwhelmed — fell short of the thesis.
• AbbVie Inc. / Cerevel Therapeutics — 2023 · $8.7B · Underwhelmed — fell short of the thesis.
• Hikma Pharmaceuticals PLC / Boehringer Ingelheim (Roxane Laboratories Inc. and Boehringer Ingelheim Roxane Inc.) — 2015 · $2.6B · Did not work — the deal failed to deliver.
• Sumitomo Dainippon Pharma Co., Ltd. (Sunovion Pharmaceuticals Inc.) / Cynapsus Therapeutics Inc. — 2016 · $624M · Did not work — the deal failed to deliver.
• Schering AG / MAP Medical Technologies Oy — 2002 · Did not work — the deal failed to deliver.
• Takeda Pharmaceutical Company Ltd. / Wave Life Sciences Ltd. — 2018 · $2.0B · Did not work — the deal failed to deliver.
• Pfizer Inc. / NextWave Pharmaceuticals, Inc. — 2012 · $700M · Did not work — the deal failed to deliver.
• Cephalon, Inc. / Mesoblast Limited — 2010 · $2.0B · Did not work — the deal failed to deliver.
• Allergan Inc. / MAP Pharmaceuticals Inc. — 2013 · $958M · Did not work — the deal failed to deliver.
• Valeant Pharmaceuticals International / Biovail Corporation — 2010 · $3.3B · Did not work — the deal failed to deliver.
• Biogen Inc. / Bristol-Myers Squibb Company — 2017 · $710M · Did not work — the deal failed to deliver.
• H. Lundbeck A/S / Prexton Therapeutics BV — 2018 · $1.1B · Did not work — the deal failed to deliver.
• Allergan plc / Naurex, Inc. — 2015 · $560M · Did not work — the deal failed to deliver.
• Pfizer Inc. / Bamboo Therapeutics, Inc. — 2016 · $645M · Did not work — the deal failed to deliver.
• Allergan plc / Heptares Therapeutics Ltd. — 2016 · $790M · Did not work — the deal failed to deliver.
• Angelini Pharma S.p.A. / Catalyst Pharmaceuticals, Inc. — 2026 · $4.1B
• InMed Pharmaceuticals Inc. / Mentari Therapeutics, Inc. — 2026 · $290M
• Eli Lilly and Company / Vaccine Company, Inc. — 2026 · $1.6B
• Otsuka Pharmaceutical Co., Ltd. / Transcend Therapeutics, Inc. — 2026 · $1.2B
• Teva Pharmaceutical Industries Ltd. / Emalex Biosciences, Inc. — 2026 · $900M
• UCB S.A. / Neurona Therapeutics, Inc. — 2026 · $1.1B
• Eli Lilly and Company / Centessa Pharmaceuticals plc — 2026 · $7.8B
• AbbVie Inc. / Gilgamesh Pharmaceuticals Inc. — 2025 · $1.2B
• Sanofi SA / Vigil Neuroscience, Inc. — 2025 · $600M
• Supernus Pharmaceuticals, Inc. / Sage Therapeutics, Inc. — 2025 · $795M
• Novartis AG / Avidity Biosciences, Inc. — 2025 · $12.0B
• Sanofi SA / ADEL, Inc. — 2025 · $1.0B
• Roche Holding AG / Ascidian Therapeutics Inc. — 2024 · $1.8B
• Takeda Pharmaceutical Company Limited / AC Immune SA — 2024 · $2.2B
• Eisai Co., Ltd. / SEED Therapeutics Inc. — 2024 · $1.5B
• AbbVie Inc. / Mitokinin, Inc. — 2023 · $655M
• F. Hoffmann-La Roche AG / Ionis Pharmaceuticals, Inc. — 2023 · $760M
• Novartis AG / Voyager Therapeutics Inc. — 2023 · $1.3B
• Recordati S.p.A. / EUSA Pharma (UK) Ltd. — 2022 · $845M
• ABL Bio Inc. / Sanofi S.A. (ABL301 license to Sanofi) — 2022 · $1.1B
• UCB S.A. / Zogenix Inc. — 2022 · $1.9B
• Novartis AG / Voyager Therapeutics Inc. — 2022 · $1.8B
• AbbVie Inc. / Sosei Group Corp. (Sosei Heptares) — 2022 · $1.3B
• AbbVie Inc. / Syndesi Therapeutics SA — 2022 · $1.0B
• Sumitomo Dainippon Pharma Co., Ltd. / Otsuka Pharmaceutical Co., Ltd. — 2021 · $270M
• Roche Holding AG / Shape Therapeutics Inc. — 2021 · $3.0B
• Roche Holding AG (Genentech) / Recursion Pharmaceuticals, Inc. — 2021 · $12.0B
• AbbVie Inc. / Calico Life Sciences LLC — 2021 · $1.0B
• GlaxoSmithKline plc / Alector, Inc. — 2021 · $2.2B
• Cerevel Therapeutics / ARYA Sciences Acquisition Corp II — 2020 · $445M
• Biogen Inc. / Sangamo Therapeutics, Inc. — 2020 · $2.7B
• H. Lundbeck A/S / Alder BioPharmaceuticals, Inc. — 2019 · $1.9B
• Eli Lilly and Company / AC Immune SA — 2019 · $1.9B
• Vertex Pharmaceuticals Incorporated / Exonics Therapeutics, Inc. — 2019 · $1.0B
• Royalty Pharma / Biohaven Pharmaceutical Holding Co. Ltd. (rimegepant funding) — 2019 · $200M
• Roche Holding AG / Skyhawk Therapeutics, Inc. — 2019 · $2.0B
• Alkermes plc / Rodin Therapeutics, Inc. — 2019 · $950M
• Pfizer Inc. / Allergan plc — 2016 · $160.0B
• AbbVie Inc. / Calico LLC — 2014 · $1.5B
• Roche Holding AG / Prothena Corporation plc — 2013 · $630M
• Endo Health Solutions Inc. / NuPathe Inc. — 2013 · $271M
• Roche Holding AG / AC Immune SA — 2012 · $418M
• Bristol-Myers Squibb Company / Allergan, Inc. (EHT/AGN 0001 license) — 2010 · $413M

← Deal Library  ·  Interactive search  ·  How we score deals